Coagulation and fibrinolysis in patients with chronic renal failure undergoing conservative treatment. 1991

S Tomura, and Y Nakamura, and F Deguchi, and R Ando, and Y Chida, and F Marumo
Department of Internal Medicine, Nakano General Hospital, Tokyo, Japan.

Eighteen patients with chronic renal failure due to primary glomerular disease undergoing conservative treatment (CRF patients) were studied to evaluate whether coagulation and fibrinolytic activity in plasma are enhanced in the patients. We measured plasma levels of coagulation-fibrinolysis parameters including thrombin-antithrombin III complex (TAT) (an index of thrombin formation), alpha 2-plasmin inhibitor (alpha 2 PI)-plasmin complex (alpha 2 PIC) (an indicator of plasmin production) and cross-linked fibrin degradation products (XL-FDP) (an index of fibrinolysis secondary to coagulation). There was no correlation between plasma levels of TAT, alpha 2PIC and XL-FDP and serum creatinine levels in CRF patients. Both fibrinogen and TAT were found to be significantly higher in CRF patients than in normal controls. TAT was negatively correlated with serum albumin or total protein. Antithrombin III (ATIII) activity was significantly lower in CRF patients than in normal controls. CRF patients showed significantly but slightly higher alpha 2 PIC and XL-FDP when compared to normal controls. These results suggest that TAT, alpha 2PIC and XL-FDP are good indicators of coagulation-fibrinolysis even in patients with decreased renal function. Coagulation activity is significantly increased in CRF patients but fibrinolysis secondary to coagulation is only slightly enhanced.

UI MeSH Term Description Entries
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D010447 Peptide Hydrolases Hydrolases that specifically cleave the peptide bonds found in PROTEINS and PEPTIDES. Examples of sub-subclasses for this group include EXOPEPTIDASES and ENDOPEPTIDASES. Peptidase,Peptidases,Peptide Hydrolase,Protease,Proteases,Proteinase,Proteinases,Proteolytic Enzyme,Proteolytic Enzymes,Esteroproteases,Enzyme, Proteolytic,Hydrolase, Peptide
D001777 Blood Coagulation The process of the interaction of BLOOD COAGULATION FACTORS that results in an insoluble FIBRIN clot. Blood Clotting,Coagulation, Blood,Blood Clottings,Clotting, Blood
D005260 Female Females
D005338 Fibrin Fibrinogen Degradation Products Soluble protein fragments formed by the proteolytic action of plasmin on fibrin or fibrinogen. FDP and their complexes profoundly impair the hemostatic process and are a major cause of hemorrhage in intravascular coagulation and fibrinolysis. Antithrombin VI,Fibrin Degradation Product,Fibrin Degradation Products,Fibrin Fibrinogen Split Products,Degradation Product, Fibrin,Degradation Products, Fibrin,Product, Fibrin Degradation
D005342 Fibrinolysis The natural enzymatic dissolution of FIBRIN. Fibrinolyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

S Tomura, and Y Nakamura, and F Deguchi, and R Ando, and Y Chida, and F Marumo
June 2004, Nihon rinsho. Japanese journal of clinical medicine,
S Tomura, and Y Nakamura, and F Deguchi, and R Ando, and Y Chida, and F Marumo
February 1989, Nihon Ketsueki Gakkai zasshi : journal of Japan Haematological Society,
S Tomura, and Y Nakamura, and F Deguchi, and R Ando, and Y Chida, and F Marumo
January 1984, Terapevticheskii arkhiv,
S Tomura, and Y Nakamura, and F Deguchi, and R Ando, and Y Chida, and F Marumo
January 1971, Scandinavian journal of haematology. Supplementum,
S Tomura, and Y Nakamura, and F Deguchi, and R Ando, and Y Chida, and F Marumo
November 1967, Polski tygodnik lekarski (Warsaw, Poland : 1960),
S Tomura, and Y Nakamura, and F Deguchi, and R Ando, and Y Chida, and F Marumo
January 1987, Zeitschrift fur arztliche Fortbildung,
S Tomura, and Y Nakamura, and F Deguchi, and R Ando, and Y Chida, and F Marumo
November 2007, Cytokine,
S Tomura, and Y Nakamura, and F Deguchi, and R Ando, and Y Chida, and F Marumo
January 1980, Sangre,
S Tomura, and Y Nakamura, and F Deguchi, and R Ando, and Y Chida, and F Marumo
January 1988, Paediatrica Indonesiana,
S Tomura, and Y Nakamura, and F Deguchi, and R Ando, and Y Chida, and F Marumo
January 1986, ASAIO transactions,
Copied contents to your clipboard!